Table 2.
Top five pathways modulated by each treatment vs. control (IKGG).
| Relevant Pathway Enrichment | Enrichment Score | p Value |
|---|---|---|
| Control vs. Fulvestrant | ||
| cAMP signaling pathway | 10.64280 | 2.39 × 10−5 |
| TGF-β signaling pathway | 8.06829 | 0.000313 |
| Complement and coagulation cascades | 6.78715 | 0.001128 |
| Calcium signaling pathway | 6.60461 | 0.001354 |
| cGMP-PKG signaling pathway | 6.35896 | 0.001731 |
| Aldosterone synthesis and secretion | 5.47526 | 0.004189 |
| Control vs. CB-103 | ||
| TGF-β signaling pathway | 4.36199 | 0.012753 |
| Bladder cancer | 3.91465 | 0.019948 |
| Arginine and proline metabolism | 3.69323 | 0.024891 |
| Drug metabolism—other enzymes | 3.22466 | 0.039770 |
| Transcriptional misregulation in cancer | 3.02111 | 0.048747 |
| Control vs. Combo | ||
| Estrogen signaling pathway | 8.35942 | 0.000234 |
| Complement and coagulation cascades | 7.10170 | 0.000824 |
| Platelet activation | 5.41271 | 0.004460 |
| Cytokine-cytokine receptor interaction | 4.75188 | 0.008635 |
| cAMP signaling pathway | 4.51626 | 0.010930 |